Insider · CIK 0001814928

Cabell Christopher

Reports to the SEC for 4 companies · WILMINGTON, DE

sec.gov

Transactions

Companies

Filings

CIK

0001814928

Forms 4 and 5

Insider transactions

16 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-21	IKTInhibikase Therapeutics, Inc.D Disposition to Issuer	President & Head of R&D	DDisposition to Issuer	−338K sh	—	—	676,564
2026-01-05	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	President & Head of R&D	AAward	+900K sh	—	—	900,117
2025-02-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	President & Head of R&D	AAward	+1.1M sh	—	—	1,100,705
2025-02-21	IKTInhibikase Therapeutics, Inc. · Stock Option (Right to Buy)A Award	President & Head of R&D	AAward	+1.1M sh	—	—	1,100,705
2023-05-18	ZURAZura Bio LtdA Award	CMO & Head of R&D	AAward	+162K sh	—	—	162,060
2023-01-26	PULMPulmatrix, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+1,700 sh	—	—	1,700
2022-01-27	PULMPulmatrix, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+22.1K sh	—	—	22,100
2021-01-28	PULMPulmatrix, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+15K sh	—	—	15,000
2020-11-25	ARENA PHARMACEUTICALS INCPerformance Restricted Stock UnitM Exercise/Conversion	EVP, Head of R&D, and CMO	MExercise/Conversion	−2,500 sh	—	—	5,000
2020-11-25	ARENA PHARMACEUTICALS INCM Exercise/Conversion	EVP, Head of R&D, and CMO	MExercise/Conversion	+2,500 sh	—	—	2,500
2020-11-25	ARENA PHARMACEUTICALS INCF Tax Payment	EVP, Head of R&D, and CMO	FTax Payment	−1,099 sh	$65.50	−$72K	1,401
2020-07-15	ARENA PHARMACEUTICALS INCS Sale	EVP, Head of R&D, and CMO	SSale	−13K sh	$68.00	−$884K	0
2020-07-15	ARENA PHARMACEUTICALS INCM Exercise/Conversion	EVP, Head of R&D, and CMO	MExercise/Conversion	+13K sh	$26.28	+$342K	13,000
2020-07-15	ARENA PHARMACEUTICALS INCEmployee Stock Option (right to buy)M Exercise/Conversion	EVP, Head of R&D, and CMO	MExercise/Conversion	−13K sh	—	—	47,000
2020-06-23	PULMPulmatrix, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+30K sh	—	—	30,000
2020-06-12	ARENA PHARMACEUTICALS INCEmployee Stock Option (right to buy)A Award	EVP, Head of R&D, and CMO	AAward	+20K sh	—	—	20,000

Recent filings

Accepted (ET)
Feb 244
Cabell Christopher0001193125-26-068077
SEC(opens sec.gov)
Jan 74
Cabell Christopher0001193125-26-006350
SEC(opens sec.gov)
Jul 24/A
Cabell Christopher0000950170-25-093445
SEC(opens sec.gov)
Feb 254
Cabell Christopher0000950170-25-026652
SEC(opens sec.gov)
May 224
Cabell Christopher0001104659-23-063312
SEC(opens sec.gov)
Jan 304
Cabell Christopher0001493152-23-002919
SEC(opens sec.gov)
Jan 314
Cabell Christopher0001493152-22-002676
SEC(opens sec.gov)
Feb 14
Cabell Christopher0001493152-21-002328
SEC(opens sec.gov)
Nov 304
Cabell Christopher0001209191-20-060721
SEC(opens sec.gov)
Jul 174
Cabell Christopher0001209191-20-042910
SEC(opens sec.gov)
Jun 254
Cabell Christopher0001493152-20-011850
SEC(opens sec.gov)
Jun 164
Cabell Christopher0001209191-20-037092
SEC(opens sec.gov)

Companies

Address

1000 N. WEST STREET, SUITE 1200

WILMINGTON, DE, 19801